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Abstract
Background: Advanced gastrointestinal stromal tumors (GISTs) can metastasize and recur after
a long remission period, resulting in serious morbidity, mortality, and complex management issues.
Case presentation: A 67-year-old woman presented with epigastric fullness, mild jaundice and
weight loss with a history of a bowel resection 7 years prior for a primary GIST of the small bowel.
The finding of a heterogeneous mass 15.5 cm in diameter replacing most of the left lobe of the liver
by ultrasonography and CT, followed by positive cytological studies revealed a metastatic GIST.
Perioperative optimization of the patient's nutritional status along with biliary drainage, and portal
vein embolization were performed. Imatinib was successful in reducing the tumor size and
facilitating surgical resection.
Conclusion:  A well-planned multidisciplinary approach should be part of the standard
management of advanced or metastatic GIST.
Background
Gastrointestinal stromal tumors (GISTs) are neoplasms of
the gastrointestinal tract. Despite their less aggressive
pathologic nature, GISTs can metastasize and recur after a
long remission period. Such cases may produce serious
morbidity, mortality, and complex management issues
for the treating physician. We hereby report the case of a
patient who presented with an isolated metastatic GIST to
the liver that was successfully treated with a multidiscipli-
nary approach including imatinib therapy, portal vein
embolization, and hepatic lobectomy.
Case presentation
A 67-year-old woman presented with epigastric fullness,
mild jaundice and a 12-pound weight loss over a period
of 3 months. The patient had a history of a bowel resec-
tion 7 years prior to presentation for an unknown malig-
nancy. On physical examination, her abdomen was soft
with a palpable and non-tender mass in the mid-epigas-
trium. Initial work-up including ultrasonography revealed
a large liver lesion, follow-up CT confirmed the presence
of a heterogeneous mass 17.5 cm in diameter replacing
most of the left lobe of the liver (Figure 1a, 1b) with
marked compression of the right biliary tree. Initial Liver
function testes showed:
total billirubin: 4, direct billirubin: 3.93, alkaline phos-
phatase: 942, AST: 124, ALT: 156. The addition laboratory
values were within normal limit.
The patient was admitted to the hospital for additional
work-up. A percutaneous transhepatic cholangiogram
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was performed, with placement of a right biliary
drainage catheter for decompression. The bilirubin
and liver function tests at the day before drainage
placement were as follow: total billirubin: 4 direct bil-
lirubin: 3.93 ALK: 942 AST: 124 ALT: 156. Two days
later the labs were as follow: total billirubin: 3.45
direct billirubin: 3.28, alkaline phosphatase: 788 AST:
117 ALT: 123, and 30 days later was: total billirubin:
0.7 direct billirubin: 0.30 alkaline phosphatase: 130
AST: 28 ALT: 25. A core liver biopsy was also done at
the time, which demonstrated atypical spindle cells.
Immuno-histochemical studies yielded positive
CD117, vimentin and actin stains, all consistent with
GIST. It was later established that the patient had pre-
viously undergone a small bowel resection for a pri-
mary GIST. Upper and lower endoscopy as well as
small bowel series were subsequently performed.
These revealed no tumors of the GI tract, suggesting
the liver mass was a late and isolated metastatic man-
ifestation of the prior GIST tumor.
A multidisciplinary and staged treatment course was rec-
ommended. Side effects and benefits of using Imatinib
drug were considered by our tumor board, and the patient
was started at a dose of 600 mg per day to reduce tumor
size. The patient was followed regularly for the next few
months as an outpatient. Her jaundice resolved and the
biliary catheter was successfully removed four months
after placement. A significant clinical improvement was
noted, with resolution of the patient's initial symptoms
and a 7-pound increase in body weight. Frequent abdom-
inal CT scans showed a hepatic mass that diminished in
size, but stabilized after 6 months of imatinib therapy at a
diameter of 11 cm (Figure 2a, 2b).
The patient then underwent portal vein embolization
(PVE) in hopes of promoting hypertrophy of the right
lobe and further atrophy of the tumor-laden left hepatic
lobe, in preparation for surgical resection.
Two months following PVE, while still on imatinib, the
patient underwent an uncomplicated left hepatic lobec-
tomy with cholecystectomy (Figure 3). Intraoperative
ultrasonography showed a hypertrophied right liver lobe,
and a 11 cm tumor involving liver segments 2, 3, 4A an
4B. Pathologic examination corroborated the diagnosis of
metastatic GIST with margins of resection free of tumor.
The patient tolerated the procedure well and was sent
home after a 14-day hospitalization. The postoperative
course was complicated by the formation of a subhepatic
abscess that was successfully treated with drainage cathe-
ters and systemic antibiotics. Imatinib was discontinued
approximately one month after surgery for a total of one
year of therapy. Follow-up CT 6 months after surgery
demonstrated no residual neoplastic disease (Figure 4a,
4b). At fourteen-months follow up, the patient was found
to be doing very well with no evidence of recurrent dis-
ease.
Discussion
Gastrointestinal stromal tumors are the most common
mesenchymal neoplasms of the GI tract. They have an
overall incidence of 3000–5000 cases per year in the
United States [1-3]. It is thought that these tumors differ-
entiate from intestinal pacemaker cells, also known as
interstitial cells of Cajal [1]. They affect mostly males
between the ages of 50 and 70, and are usually found inci-
dentally at early stages [1-4]. Large or advanced lesions
may present with a variety of clinical findings, including
bleeding, abdominal pain, early satiety, bowel obstruc-
tion, or perforation.
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GISTs are usually detected by endoscopy, CT or MRI per-
formed for abdominal symptoms. The gold standard for
diagnosing GISTs is pathological tissue examination,
which normally demonstrates atypical splindle cells. A
positive stain for CD117 carries a specificity of 95% for
these tumors, and will unequivocally establish a diagnosis
[1-7].
When GISTs originate in the small bowel, they behave in
a more aggressive manner [8]. The most common site for
metastases is the liver and the peritoneal cavity, but can
also occur in bone, skin, soft tissues, and lymph nodes [5].
Negative prognostic factors for aggressiveness and recur-
rence include tumor size, a high mitotic index, or an
unknown site of origin [9,10]. Recurrence usually occurs
19–26 months after surgery [3,11,12]. For this reason, the
National Comprehensive Cancer Network suggests rou-
tine follow-up CT scans of the abdomen and pelvis every
3–6 month for the first 3–5 years after resection [7].
The only definitive treatment for GISTs is surgical resec-
tion. This can be done laparoscopically in some cases, or
with the traditional open approach. The mainstay of sur-
gical therapy in primary or metastatic disease is to achieve
a complete resection with negative margins [7]. Conven-
tional chemotherapy and radiation therapy may have
minor adjunctive benefits in unresectable or metastatic
GISTs [2]. Imatinib mesylate (Gleevec®), a selective inhib-
itor of tyrosine kinase, has revolutionized the manage-
ment of this disease in recent years. Imatinib has a
significant shrinking effect on GISTs, and can be used
when primary GISTs have attained a very large size or are
in unfavorable locations, increasing the risk of positive
resection margins [1]. Imatinib has also become the first
line of treatment for recurrent and/or metastatic GISTs, as
described for the patient in this case report [13]. Imatinib
is generally very well tolerated; and most patients can tol-
erate treatment without interruption. The more common
side effects of Imatinib mesylate include [14,15]: nausea,
vomiting, diarrhea, and muscle cramps. It is common to
see a decrease in the neutrophil and platelet counts espe-
cially during the first month of therapy [16]. The drug
should be stopped to allow recovery if the absolute neu-
trophil count (ANC) falls to <1,000/microL and/or the
platelet count to <50,000/microL during the first months
of therapy [17]. Our patient had no evidence of these side
effects during therapy. More recently, sunitinib malate
(Sutent®), a multikinase inhibitor has been approved by
the Food and Drug Administration for treatment of GISTs
that are refractory to imatinib [18].
Resection of GIST liver metastases may be curative when
the primary disease has been eradicated and negative sur-
gical resection margins are attained. However, a large
tumor burden in the hepatic parenchyma may prohibit
resection given the risk of insufficient remaining liver tis-
sue and subsequent postoperative liver failure [19]. An
option to counteract this phenomenon is the use of portal
vein embolization (PVE) in cases of unilobular involve-
ment of the liver. First used in the 1980s, selective PVE
induces atrophy of a selected liver region as well as a com-
pensatory hypertrophy of the remaining liver parenchyma
[20-23]. Preoperative PVE is recommended if less than
30% to 40% of normal the liver is expected to remain and
be functional after resection [24,25].
Conclusion
This case, to our best knowledge, represents the first in the
literature describing a multidisciplinary approach for the
successful management of a large metastasic GIST to the
liver. We attribute the success of this case to a well thought
out management plan set forth by a dedicated tumor
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board utilizing advanced and evidence-based therapeutic
modalities. Timing and resource utilization were key fac-
tors in the management of this patient. Perioperative opti-
mization of the patient's nutritional status and state of
health with biliary drainage was helpful. The pharmaco-
logic effect of imatinib reduced the tumor size and
improved the surgical resectability. Additionally, PVE
facilitated the operation and promoted healthy liver tissue
hypertrophy. Lastly, careful operative technique and ded-
icated follow up allowed for a good surgical outcome in
this patient. A well-planned multidisciplinary approach
should be part of the standard management of advanced
or metastatic GISTs.
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